This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Smartphone simple

Most people living with type 2 diabetes will have some digital know-how, and Dose Check is designed to be simple to use.1
Guiding your patients smoothly

Dose Check prompts patients to log their fasting blood glucose and inject the recommended insulin dose every day to help them reach their target blood glucose level.†1-3 You can view this data through the Dose Check Dashboard.

 

†Dose guidance is based on the data the patient records, taking into consideration the average of three consecutive blood glucose readings and last insulin injection.
Quick and easy for you to set up through the Dose Check Dashboard

Dose Check is designed to be as simple for you to set up as it is for patients to use.1 You can choose a pre-set treatment plan or create your own - and you can monitor your patients' progress in managing their diabetes.1

You can set up Dose Check for patients through the Dose Check Dashboard via PC or mobile phone browser.1

Dose Check's dosing guidance is designed to simplify starting and titrating a new basal insulin.1,2 And supporting patients in using Dose Check and self-titrating, so they are on the right dose, may prevent long-term health complications.3, 5-8

Dose Check is a software developed to assist healthcare professionals and patients in the process of titration for selected Novo Nordisk insulins with the follow-up of the responsible healthcare professional. Dose Check does not make any type of diagnosis. It does not substitute the professional medical advice given by doctors, physicians or diabetes care teams.

Any healthcare professional can register free of charge through the Dose Check Dashboard in countries where Dose Check is available. You can access the Dose Check Dashboard via your PC or mobile phone browser.

Dose Check provides guidance for selected Novo Nordisk insulins. Please contact your local Novo Nordisk representative for more information.

Please contact your Novo Nordisk representative to ask if Dose Check is available in your respective country. Healthcare professionals need to register with Dose Check to gain access to the Dose Check Dashboard to set up patients and initiate use.

Novo Nordisk will not have access to data that enables identification of patients registered with Dose Check. All data that may identify a patient such as name, telephone number or date of birth is stored only by the legal manufacturer Amalgam and is not transferred to Novo Nordisk or any third party. For more information about data protection and data privacy, refer to the Dose Check Privacy Policy.
 

Reference not found

digital health article image

With our digital therapeutic technologies and device innovations, we aim to improve the health and well-being of people living with diabetes around the world.
Smart pens. Smarter Care

The smart insulin pens NovoPen® 6 & NovoPen Echo® Plus are designed to improve insulin dose recording. This may help HCPs to have informed discussions with patients with type 2 diabetes based on individual injection data.1,12-14
Digital Health Partnerships

Get to know the ecosystem of Novo Nordisk’s digital health partners.

1.

Data on file: Technical Specification Document & Device Description (DDSC-1) Amalgam Guide.

2.

Dose Check Evidence Based Titration Protocols – Reference Document.

3.

Clinical Evaluation Report for iSage Rx and Dose Check Software Application (CER-001) Ver. 13.

4.

Grdinovac K et al. Diabetes 2019; 68:122-LB.

5.

Russell-Jones D et al. Diabetes Obes Metab 2018; 20(3): 488–496.

6.

UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):837–53.

7.

The Diabetes Control and Complications Trial Research Group. Diabetes 1995; 44(8):968–83.

8.

Stratton IM et al. BMJ 2000; 321(7258):405–12.

9.

Allen NA et al. J Clin Transl Endocrinol 2016; 7:1–6.

10.

Berard L et al. Diabetes Obes Metab 2018; 20: 301–308.

11.

Curtis B, Lage MJ. J Med Econ 2014; 17:1, 21–31.


12.

NovoPen®6 User Guide.

13.

NovoPen Echo®Plus User Guide.

14.

Klonoff DC et al. J Diabetes Sci Technol 2018; 12(3)551–558.

Manufacturer

Amalgam Rx, Inc.

1007 N. Orange St.

Ste. 400

Wilmington, DE 19801

USA

 

Authorized Representative

Medical Device Safety Service Gmbh

Schiffgraben 41

30175 Hannover

Germany

 

 

Dose Check is CE marked. Notified body 1282. Dose Check is certified against the EU Medical Device Directive (MDD), 93/42/EEC.
Manufacturer: Amalgam Rx, Inc. 1007 N. Orange St, Ste. 400, Wilmington, DE 19801, USA Authorized Representative: Medical Device Safety Service GmbH, Schiffgraben 41, 30175 Hannover, Germany.
Dose Check is available in a number of countries and additional launches are planned in the near future. Time frames will vary according to device, insulin brand and unique market regulations. Dose guidance apps and the information contained in these materials are not intended as a substitute for professional medical advice.

 

NovoPen® 6 and NovoPen Echo® Plus are CE-marked medical devices. Notified body 0123. 

NovoPen® 6 and NovoPen Echo® Plus are certified against the EU Medical Device Directive (MDD) 93/42/EEC.

NovoPen® 6 and NovoPen Echo® Plus are available in a number of countries with additional launches planned in the near future. Timeframes will vary according to device, insulin brand and unique market regulations.

 

The information contained on this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is suitable for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness, or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.

 

HQ24DC00016, May 2024